Publications by authors named "Setareh Dashti Shokoohi"
Article Synopsis
- Ovarian cancer is a leading cause of cancer-related deaths in women, often diagnosed at late stages with a low five-year survival rate of around 30%.
- Traditional treatment involves surgery and chemotherapy, but many patients experience tumor relapse and few immunotherapies have been approved for ovarian cancer.
- This review discusses the potential and challenges of CAR-T therapy for ovarian cancer, highlighting the progress and limitations faced when targeting solid tumors with this innovative treatment.
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies.
View Article and Find Full Text PDF